NCT00662909View on ClinicalTrials.gov

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

2,149

Participants

Timeline

Start Date

March 28, 2008

Primary Completion Date

April 22, 2009

Study Completion Date

April 22, 2009

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Mirabegron

Oral

DRUG

Placebo

Oral

Trial Locations (125)

11530

Garden City

12208

Albany

12401

Kingston

12601

Poughkeepsie

13760

Endwell

17604

Lancaster

19004

Bala-Cynwyd

19114

Philadelphia

19611

Reading

20770

Greenbelt

23502

Norfolk

27103

Winston-Salem

27518

Cary

28025

Concord

28209

Charlotte

28401

Wilmington

29464

Mt. Pleasant

29650

Greer

29681

Simpsonville

30005

Alpharetta

30034

Decatur

30076

Roswell

30308

Atlanta

30328

Atlanta

32308

Tallahassee

32803

Orlando

33024

Pembroke Pines

33027

Pembroke Pines

33180

Aventura

33407

West Palm Beach

33414

Wellington

33606

Tampa

33756

Clearwater

33761

Clearwater

33916

Fort Myers

34237

Sarasota

34471

Ocala

34747

Celebration

35209

Homewood

35801

Huntsville

36117

Montgomery

36608

Mobile

37620

Bristol

43214

Columbus

44122

Cleveland

44124

Lyndhurst

44281

Wadsworth

45212

Cincinnati

46825

Fort Wayne

47130

Jeffersonville

47630

Newburgh

50309

Des Moines

57207

Wichita

58104

Fargo

59102

Billings

60160

Melrose Park

64116

North Kansas City

68114

Omaha

68516

Lincoln

71106

Shreveport

73008

Bethany

73034

Edmond

75231

Dallas

76017

Arlington

77024

Houston

78229

San Antonio

78414

Corpus Christi

78759

Austin

80012

Aurora

80112

Englewood

80211

Denver

80218

Denver

83404

Idaho Falls

83814

Coeur d'Alene

84107

Salt Lake City

85051

Phoenix

85712

Tucson

85741

Tucson

87109

Albuquerque

89148

Las Vegas

90017

Los Angeles

90211

Beverly Hills

90505

Torrance

90620

Buena Park

91345

Mission Hills

91356

Tarzana

91506

Burbank

91942

La Mesa

92108

San Diego

92120

San Diego

92404

San Bernardino

92660

Newport Beach

92869

Orange

93720

Fresno

94027

Atherton

94102

San Francisco

95608

Carmichael

95816

Sacramento

98043

Mountlake Terrace

98166

Seattle

98405

Tacoma

99204

Spokane

99508

Anchorage

06052

New Britain

06708

Waterbury

01103

Springfield

02472

Watertown

07052

West Orange

02886

Warwick

V3V 1N1

Surrey

V8T 5G1

Victoria

E2L 3J8

Saint Johns

L4M 7G1

Barrie

L6T 4S5

Brampton

N2N 2B9

Kitchener

L3X 1W1

Newmarket

P1B 7K8

North Bay

L1H 1B9

Oshawa

M4K 2J1

Owen Sound

P7E 6E7

Thunder Bay

M4N 3M5

Toronto

M5T 2S8

Toronto

M6S 4W4

Toronto

J2G 8Z9

Granby

H9R 4S3

Pointe-Claire

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00662909 - A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | Biotech Hunter | Biotech Hunter